Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03174327
Other study ID # 35RC17_9881_SUPERSONIC
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 27, 2017
Est. completion date April 24, 2018

Study information

Verified date May 2023
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Interventional study with minimal risks and constraints, prospective, mono-centric.


Description:

Ultrasonic impulse elastography is a technique for studying non-invasive tissue rigidity. In particular, it is used in hepatology to assess the degree of fibrosis in a simple manner, by eliminating, in a number of cases, liver biopsy. The investigation of fibrosis is an essential element in the follow-up of patients with hepatic transplant since it is the indirect sign of a post-transplant complication or a recurrence of the initial disease. Several elastography devices are available on the market, using different technologies to measure the rigidity of tissues. Studies have shown that the first hepatic elastography devices, Fibroscan® and Acoustic Radiation Force Impulse (ARFI) can detect significant fibrosis on hepatic grafts accurately and reproducibly. However, there are several factors related to patients or to the elastography apparatus itself, limiting its use by making the collection of measurements impossible or by giving outliers. In addition, first-generation devices (Fibroscan®) are not coupled to a conventional ultrasound system and are dedicated to the measurement of hepatic rigidity, so patients must undergo systematic ultrasound as part of graft follow-up . Supersonic® (SuperSonic Imagine, Aix-en-Provence, France) is part of the latest generation of elastography devices and is based on ultrafast shearwave elastography (SWE) technology. This device is a conventional ultrasound system for routine ultrasound scanning with an integrated module for measuring tissue stiffness, and has the advantage of establishing real-time mappings of tissue rigidity over a large area. Several studies have shown that the measurements were reliable and reproducible, especially in the assessment of liver stiffness. In the literature, only one study addressed the measurement of hepatic rigidity with the Supersonic® ultrasound system in liver transplant patients and was designed to diagnose viral hepatitis recurrence or acute cellular rejection. In the secondary results, the authors found a significantly higher hepatic rigidity of healthy hepatic grafts compared to healthy native livers. It is proposed to add to the ultrasound of systematic follow-up of the hepatic grafts carried out in clinical routine an elastographic measurement in order to assess the hepatic rigidity in these patients in a non-invasive way.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date April 24, 2018
Est. primary completion date April 24, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women aged 18 years and over ; - Hepatic transplant patient attending a day hospital of hepatology as part of the systematic follow-up of liver transplantation at 1 year, 5 years or 10 years in order to benefit from a clinical examination, biological evaluation, hepatic ultrasound, Fibroscan and Hepatic Puncture-Biopsy ; - Patient in a position to receive information about the protocol ; - Patient having given his / her written consent. Exclusion Criteria: - Coagulation disorder (platelets <60,000, Prothrombin Ratio <50%, partial thromboplastin time > 1.5 times the control unless explained by insufficient factor XII deficiency or anti-phospholipid antibodies); - Ascites; - Platelet antiaggregation taken the previous week biopsy, patient under anticoagulants; - Persons of full age who are subject to legal protection (safeguard of justice, guardianship, guardianship), persons deprived of their liberty; - Patient not affiliated to social security; - Pregnant or nursing women; - Simultaneous participation in another research.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Hepatic Transplantation
Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.

Locations

Country Name City State
France Rennes University Hospital Rennes

Sponsors (1)

Lead Sponsor Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

References & Publications (1)

Dubois M, Ronot M, Houssel-Debry P, Brun V, Rayar M, Auger M, Beuzit L, Turlin B, Aube C, Paisant A. Performance of B-mode ratio and 2D shear wave elastography for the detection and quantification of hepatic steatosis and fibrosis after liver transplantat — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Hepatic graft stiffness in kPa without complication Average of the three measures taken consecutively Baseline
Secondary Hepatic graft stiffness in kPa with complication Average of the three measures taken consecutively Baseline
Secondary The performance indicator Evaluation of the diagnostic performance of Supersonic® and Fibroscan versus Hepatic Puncture-Biopsy (sensitivity, specificity, reproducibility). Baseline
Secondary The value of the hepatic steatosis of the grafts in the form of a ratio The value of the hepatic steatosis of the grafts in the form of a ratio between the hepatic brightness and the renal brightness. Baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05047406 - Bacillus Clausii in Liver Transplantation Phase 2
Completed NCT02853981 - Clamp-crush Technique Versus Harmonic Scalpel in Living Donor Hepatectomy Phase 2/Phase 3
Completed NCT01388387 - Pharmacogenetic Study of Tacrolimus in Hepatic Transplant (CYPTAC'H) N/A